PLAGL2 and central nervous system cancer: According to Timer analysis, PLAGL2 was upregulated in bladder, breast, cervix, bile ducts, colorectal, esophagus, kidney, liver, lung, stomach, and CNS cancer compared with normal cases (Figure 1A, Supplementary Table S1), whereas it was downregulated in renal and thyroid cancers.